Page 1

Siegfried T Media Release Evolving in Challenging Times : Siegfried Rises to the Next Level The Siegfried Group reports sales of 845.1 million Swiss francs for the 2020 financial year , representing an increase of 1.4 percent in Swiss francs and 4.5 percent in local currencies . Earnings before interest , taxes , depreciation and amortization ( Core EBITDA ) grew by 6.2 percent to 149.4 million Swiss francs . This corre sponds to a Core EBITDA margin of 17.7 percent , a plus of 0.8 percentage points compared to the previous year . Core net profit of 72.2 million Swiss francs is also higher than in the previ ous year ( 65.7 million ) , an increase of 10.4 percent . Siegfried has signed a cooperation and supply agreement with the Ger man company Biopharmaceutical New Technologies ( BioNTech ) for the aseptic filling ( " Fill & Finish " ) and packaging of large commercial quantities of the COVID - 19 mRNA vaccine BNT162b2 ( " Comirnaty " ) and will thus make an important contribution to the global fight against the Corona virus pandemic from mid - 2021 onwards . With the acquisition of two large Drug Products sites from Novartis in Bar celona with approximately 1'000 employees , Siegfried has implemented a significant strategic step . The Board of Directors proposes to the Annual General Meeting to in crease the distribution to the shareholders by 20 cents to 3.00 Swiss francs per registered share ( previous year : CHF 2.80 ) . This will be effected by re ducing the nominal value as part of a capital reduction . www.siegfried.ch Zofingen , 24 February 2021